Maraviroc in Antiretroviral-Naïve HIV-1 Patients
New antiretroviral agents that are better tolerated with less side effects and novel resistance patterns are needed at all lines of human immunodeficiency virus (HIV) therapeutic strategies. The CC-chemokine receptor 5 (CCR5) antagonist maraviroc is a member of the novel class of “antiretroviral age...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2012-01-01
|
| Series: | Infectious Diseases |
| Online Access: | https://doi.org/10.4137/IDRT.S7597 |